[go: up one dir, main page]

PE20020384A1 - PEPTIDOS COMO INHIBIDORES DE LA PROTEASA SERINA NS3/NS4a DEL VIRUS DE LA HEPATITIS C - Google Patents

PEPTIDOS COMO INHIBIDORES DE LA PROTEASA SERINA NS3/NS4a DEL VIRUS DE LA HEPATITIS C

Info

Publication number
PE20020384A1
PE20020384A1 PE2001000732A PE2001000732A PE20020384A1 PE 20020384 A1 PE20020384 A1 PE 20020384A1 PE 2001000732 A PE2001000732 A PE 2001000732A PE 2001000732 A PE2001000732 A PE 2001000732A PE 20020384 A1 PE20020384 A1 PE 20020384A1
Authority
PE
Peru
Prior art keywords
hepatitis
inhibitors
peptides
ns4a protease
virus
Prior art date
Application number
PE2001000732A
Other languages
English (en)
Inventor
Ashok Arasappan
Zhaoning Zhu
Stephane L Bogen
Tin-Yau Chan
Kevin X Chen
Ashit K Ganguly
Vyyoor Moopil Girijavallabhan
Siska Hendrata
Yushua Huang
Edwin E Jao
Scott Jeffrey Kemp
Odile Esther Levy
Marguerita Lim-Wilby
Yi-Tsung Liu
Raymond G Lovey
Jinping L Mccormick
George F Njoroge
Tejal N Parekh
Rusell E Pike
Patrick A Pinto
Anil K Saksena
Bama Santhanam
Susan Y Tamura
Henry A Vaccaro
Srikanth Venkatraman
Haiyan Wang
Wanli Wu
Frank Bennett
Original Assignee
Schering Corp
Dendreon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22822136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20020384(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp, Dendreon Corp filed Critical Schering Corp
Publication of PE20020384A1 publication Critical patent/PE20020384A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A COMPUESTOS PEPTIDICOS QUE INCLUYEN ENANTIOMEROS, ESTEREOISOMEROS, ROTAMEROS, TAUTOMEROS, RACEMATOS COMO INHIBIDORES DE LA PROTEASA SERINA NS3/NS4a DEL VIRUS DE LA HEPATITIS C. SE REFIERE TAMBIEN A PROCEDIMIENTO PARA LA PREPARACION Y COMPOSICIONES FARMACEUTICAS UTILES PARA EL TRATAMIENTO DE TRASTORNOS ASOCIADOS CON LA PROTEASA SERINA NS3/NS4 DEL VIRUS DE LA HEPATITIS C
PE2001000732A 2000-07-21 2001-07-19 PEPTIDOS COMO INHIBIDORES DE LA PROTEASA SERINA NS3/NS4a DEL VIRUS DE LA HEPATITIS C PE20020384A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22011800P 2000-07-21 2000-07-21

Publications (1)

Publication Number Publication Date
PE20020384A1 true PE20020384A1 (es) 2002-05-28

Family

ID=22822136

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000732A PE20020384A1 (es) 2000-07-21 2001-07-19 PEPTIDOS COMO INHIBIDORES DE LA PROTEASA SERINA NS3/NS4a DEL VIRUS DE LA HEPATITIS C

Country Status (4)

Country Link
US (2) US6953802B2 (es)
AU (1) AU2001276022A1 (es)
PE (1) PE20020384A1 (es)
WO (1) WO2002008201A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI281470B (en) * 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
AU2004251754A1 (en) * 2003-06-25 2005-01-06 Elan Pharmaceuticals, Inc. Methods and compositions for treating rheumatoid arthritis
WO2006062972A2 (en) * 2004-12-08 2006-06-15 Bristol-Myers Squibb Company Heterocyclic compounds as inhibitors of factor viia
MY151045A (en) 2006-02-27 2014-03-31 Elan Pharm Inc Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
US20080319652A1 (en) * 2007-06-20 2008-12-25 Radiofy Llc Navigation system and methods for map navigation
WO2011020874A1 (en) 2009-08-20 2011-02-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
CN112969687B (zh) 2018-10-30 2024-08-23 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
ES3003232T3 (en) 2018-10-30 2025-03-10 Gilead Sciences Inc Compounds for inhibition of alpha4beta7 integrin
CA3115820A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
EP3873900B1 (en) 2018-10-30 2025-01-08 Gilead Sciences, Inc. Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
CA3148613A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Phenylalanine derived compounds and their use as inhinitors of alpha 4 beta 7 integrin
US20240301512A1 (en) 2021-01-29 2024-09-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330506A3 (en) 1988-02-26 1990-06-20 Dana Farber Cancer Institute Vla proteins
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
CA2193508A1 (en) 1994-07-11 1996-01-25 Eugene D. Thorsett Inhibitors of leukocyte adhesion

Also Published As

Publication number Publication date
US20050192280A1 (en) 2005-09-01
WO2002008201A2 (en) 2002-01-31
US7223762B2 (en) 2007-05-29
US20020058664A1 (en) 2002-05-16
AU2001276022A1 (en) 2002-02-05
US6953802B2 (en) 2005-10-11
WO2002008201A3 (en) 2002-06-27

Similar Documents

Publication Publication Date Title
EP1771454A4 (en) PEPTIDE ANALOGUE AS HEPATITIS C HEMMER
TW200615275A (en) Hepatitis C inhibitor dipeptide analogs
DE122012000004I1 (de) Peptide als inhibitoren der NS3-Serinprotease des hepatitis c virus.
PE20020384A1 (es) PEPTIDOS COMO INHIBIDORES DE LA PROTEASA SERINA NS3/NS4a DEL VIRUS DE LA HEPATITIS C
CL2012000919A1 (es) Composicion que comprende un compuesto derivado de metoxicarbonil-amino-metilbutanoil-pirrolidinil-imidazol de formula i, inhibidor especifico de ns5a de hcv, y un compuesto derivado de oxo-pirrolidin-quinoleina de formula ii, inhibidor de proteasa ns3 de hcv; y uso en el tratamiento de la hepatitis c.
AR030591A1 (es) Inhibidores de proteasa peptidomimetica
GEP20104956B (en) Compounds for inhibiting hepatitis c viral replication and use thereof
UY28525A1 (es) Péptidos macrociclicos activos contra en virus de la hepatitis c
NO20042792L (no) Nye peptider som NS3-serinproteaseinhibitorer for hepatitt C-virus
DOP2009000094A (es) Inhibidores de la proteasa ns3 del hcv
ES2240446T3 (es) Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c.
ATE486889T1 (de) Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
IL176237A0 (en) Inhibitors of hepatitis c virus ns3/ns4a serine protease
ATE474827T1 (de) Hcv-replikationshemmer
WO2007016476A3 (en) Hepatitis c serine protease inhibitors and uses therefor
ATE438622T1 (de) 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
ATE513844T1 (de) Acylsulfonamidverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
ECSP056181A (es) Compuestos Inhibidores de la Hepatitis C
ATE497505T1 (de) Makrocyclische inhibitoren der ns3-serinprotease des hepatitis-c-virus
CR9731A (es) Inhibidores de proteasa ns3 del vhc
ATE434621T1 (de) Neue verbindungen als inhibitoren der ns3- serinprotease des hepatitis-c-virus
TW200602037A (en) Novel compounds as inhibitors of hepatitis C virus NS3 serine protease
CL2012000054A1 (es) Composicion farmaceutica líquida que comprende a) un compuesto derivado de quinoleina-2,4,7,8-sustituida, inhibidor de la serina proteasa ns3 del virus de la hepatitis c (vhc), b) uno o mas lipidos, y c) uno o mas tensioactivos hidrofilos.
CL2008003267A1 (es) Compuestos derivados de macrociclos fusionados con pirrolidina, inhibidores de la serina proteasa ns3; composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en la preparacion de medicamentos para el tratamiento de la hepatitis c.
UY26100A1 (es) Peptidos macrociclicos activos frente al virus de la hepatitis c

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration
FD Application declared void or lapsed